A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO

Evangelos Terpos; Meletios A Dimopoulos; Efstathios Kastritis; Jordan M. Schecter; Jon Ukropec; Elena Smith; Pieter Sonneveld

doi:10.1093/annonc/mdx373.041

Article2018

Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Pieter Sonneveld, Evangelos Terpos, Meletios A Dimopoulos, Jon Ukropec, Elena Smith, Nienke Houkes, Jordan M. Schecter, Efstathios Kastritis

Article2021

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Pieter Sonneveld, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, María‐Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Yanping Qiu, Himal Amin, Michele Kosh, NamPhuong Tran, Robin Carson, Meletios A Dimopoulos

Article2023

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos,

Article2021

OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Pawef Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek,

Article2021

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis

Meletios A Dimopoulos, Fredrik Schjesvold, María‐Victoria Mateos, Paweł Robak, Roman Hájek, Paul G. Richardson, Jakob Lindberg, Marcus Thuresson, Kajsa Larsson, Pieter Sonneveld

A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO

Discussion(0)

Related publications

Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis